Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

An anti-new coronavirus fully human broad-spectrum neutralizing antibody zwc12 and its application

A fully human, monoclonal antibody technology used in the fields of microbiology and immunology to solve problems such as loss of neutralizing activity

Active Publication Date: 2022-03-25
ACADEMY OF MILITARY MEDICAL SCI
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, with the continuous evolution and mutation of SARS-CoV-2, most of the monoclonal antibodies under development have lost their neutralizing activity against one or more mutant strains. Among them, LY-CoV555 and LY-CoV016 developed by Eli Lilly, regeneration REGN10933 developed by Yuan has lost neutralizing activity against Beta strain virus, and antibody drug LY-CoV555-LY-CoV016 cocktail therapy, REGEN-COV cocktail therapy, AZD7442 cocktail therapy have lost neutralizing activity against Omicron strain

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • An anti-new coronavirus fully human broad-spectrum neutralizing antibody zwc12 and its application
  • An anti-new coronavirus fully human broad-spectrum neutralizing antibody zwc12 and its application
  • An anti-new coronavirus fully human broad-spectrum neutralizing antibody zwc12 and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1 Screening and preparation of human anti-SARS-CoV-2 monoclonal antibodies.

[0037] 1. Collection of blood samples.

[0038] After obtaining informed consent, 20 mL of blood samples were collected from the recipients immunized with the recombinant novel coronavirus vaccine 14 days after the second immunization for subsequent experiments.

[0039] 2. Sorting memory B cells by flow cytometry.

[0040] The collected blood samples were separated from PBMC by Ficoll density gradient centrifugation, and the process was as follows:

[0041] 1) Take fresh anticoagulated whole blood and anticoagulate with EDTA.

[0042] 2) Add the same volume of separation liquid as the blood sample into the centrifuge tube, spread the blood sample above the liquid surface of the separation liquid, and keep the interface between the two liquid surfaces clear.

[0043] 3) Trim, room temperature, horizontal rotor 800 g, acceleration and deceleration speed 3, centrifuge for 30 min.

[...

Embodiment 2

[0119] Example 2. Analysis of the epitope recognized by antibody ZWC12.

[0120] 1) Coating: Take the recombinant SARS-CoV-2 WT (new crown wild strain Genbank number: NC_045512.2) S-ECD antigen, S1 antigen, RBD antigen and S2 antigen on the 96-well enzyme-linked plate the day before the experiment. solution diluted to a concentration of 2 μg / mL, coated with 100 μL per well, and coated overnight at 4°C.

[0121] 2) Blocking: Wash 3 times with a plate washer (BIO-TEK, 405_LS) on the day of the experiment, add 100 µL of blocking solution to each well, and incubate at 37°C for 1 hour.

[0122] 3) Sample incubation: wash the plate 3 times, add 100 μL diluent to each well except the first well, dilute the antibody to 1 μg / mL in the first well, 4-fold serial dilution, 100 μL / well, set three for each antibody Duplicate the wells and incubate at 37°C for 1 h.

[0123] 4) Secondary antibody incubation: wash the plate 3 times, dilute the HPR-labeled goat anti-human IgG secondary antibo...

Embodiment 3

[0129] Example 3: Identification of cross-binding activity of antibody ZWC12.

[0130] The cross-binding activity between ZWC12 and the S protein of SARS-CoV-2 variants of concern (Variants of concern) was identified, the method is the same as above, and the results are as follows Figure 7 shown. ZWC12 specifically binds to the S-ECD protein of Alpha strain, Beta strain, Gamma strain, Delta strain, and Omicron strain, and exhibits a dose-response relationship. The results showed that monoclonal antibody ZWC12 could cross-link the S-ECD protein of Alpha strain, Beta strain, Gamma strain, Delta strain and Omicron strain.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an anti-SARS-CoV-2 fully human monoclonal antibody ZWC12. The antibody has a unique CDR partition, and its antigen recognition epitope is located in the RBD region of the S1 protein. The antibody neutralizes the EC of the new coronavirus wild type, Alpha, Beta, Gamma, Delta, Omicron mutant strain pseudovirus 50 They are 1.041, 0.124, 0.162, 0.136, 0.411, and 0.093 μg / mL, respectively. The antibody has broad-spectrum and high-efficiency neutralization activity against the current main mutant strains. The antibody also has the characteristics of high expression, full human origin, and good stability, is suitable for industrial production, and has important application value for responding to the outbreak caused by the new crown mutant strain.

Description

technical field [0001] The invention discloses an antibody and belongs to the fields of microbiology and immunology. Background technique [0002] The pathogen of new coronary pneumonia (COVID-19) is novel coronavirus-2 (SARS-CoV-2). RNA virus, its genome length is about 30 kb. The first 2 / 3 of the genome is the non-structural gene ORF1a / b, which mainly encodes enzymes related to viral replication (RNA-dependent RNA polymerase, RdRp), and the last 1 / 3 encodes four structural proteins in turn: spike protein (S), Envelope protein (E), membrane protein (M) and nucleocapsid protein (N). Among them, the S protein contains a virus receptor binding region, which can bind to the angiotensin-converting enzyme 2 (ACE2) receptor on the surface of human cells, mediate virus adsorption and entry into cells, and is a key protein for virus invasion of host susceptible cells. [0003] The virus will continuously mutate randomly during the transmission process, some of which will enhance ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/10C12N15/13C12N15/85C12N5/10A61K39/42A61P31/14
CPCC07K16/10C12N15/85A61P31/14C07K2317/56C07K2317/565C07K2317/33C07K2317/76C07K2317/92C12N2800/107A61K2039/505
Inventor 陈薇于长明迟象阳孙韩聪张冠英张军李建民范鹏飞陈郑珊张哲王步森宰晓东房婷付玲郝勐陈旖徐婧含
Owner ACADEMY OF MILITARY MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com